Division of Cardiovascular Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester Academic Health Science Centre, Manchester, UK.
Department of Pharmacy, Faculty of Medicine, Universitas Brawijaya, Malang, Indonesia.
Br J Pharmacol. 2019 Oct;176(20):3956-3971. doi: 10.1111/bph.14795. Epub 2019 Oct 8.
The Hippo pathway has emerged as a potential therapeutic target to control pathological cardiac remodelling. The core components of the Hippo pathway, mammalian Ste-20 like kinase 1 (Mst1) and mammalian Ste-20 like kinase 2 (Mst2), modulate cardiac hypertrophy, apoptosis, and fibrosis. Here, we study the effects of pharmacological inhibition of Mst1/2 using a novel inhibitor XMU-MP-1 in controlling the adverse effects of pressure overload-induced hypertrophy.
We used cultured neonatal rat cardiomyocytes (NRCM) and C57Bl/6 mice with transverse aortic constriction (TAC) as in vitro and in vivo models, respectively, to test the effects of XMU-MP-1 treatment. We used luciferase reporter assays, western blots and immunofluorescence assays in vitro, with echocardiography, qRT-PCR and immunohistochemical methods in vivo.
XMU-MP-1 treatment significantly increased activity of the Hippo pathway effector yes-associated protein and inhibited phenylephrine-induced hypertrophy in NRCM. XMU-MP-1 improved cardiomyocyte survival and reduced apoptosis following oxidative stress. In vivo, mice 3 weeks after TAC, were treated with XMU-MP-1 (1 mg·kg ) every alternate day for 10 further days. XMU-MP-1-treated mice showed better cardiac contractility than vehicle-treated mice. Cardiomyocyte cross-sectional size and expression of the hypertrophic marker, brain natriuretic peptide, were reduced in XMU-MP-1-treated mice. Improved heart function in XMU-MP-1-treated mice with TAC, was accompanied by fewer TUNEL positive cardiomyocytes and lower levels of fibrosis, suggesting inhibition of cardiomyocyte apoptosis and decreased fibrosis.
The Hippo pathway inhibitor, XMU-MP-1, reduced cellular hypertrophy and improved survival in cultured cardiomyocytes and, in vivo, preserved cardiac function following pressure overload.
Hippo 通路已成为控制病理性心脏重构的潜在治疗靶点。Hippo 通路的核心组成部分,哺乳动物 Ste-20 样激酶 1(Mst1)和哺乳动物 Ste-20 样激酶 2(Mst2),调节心脏肥大、细胞凋亡和纤维化。在这里,我们使用一种新型抑制剂 XMU-MP-1 研究了抑制 Mst1/2 对控制压力超负荷诱导的肥大不良影响的作用。
我们分别使用培养的新生大鼠心肌细胞(NRCM)和 C57Bl/6 小鼠的横主动脉缩窄(TAC)作为体外和体内模型,以测试 XMU-MP-1 治疗的效果。我们使用荧光素酶报告基因检测、Western blot 和免疫荧光检测进行体外实验,使用超声心动图、qRT-PCR 和免疫组织化学方法进行体内实验。
XMU-MP-1 处理显著增加 Hippo 通路效应物 yes 相关蛋白的活性,并抑制苯肾上腺素诱导的 NRCM 肥大。XMU-MP-1 改善了氧化应激后心肌细胞的存活并减少了细胞凋亡。在体内,TAC 后 3 周的小鼠,每隔一天用 XMU-MP-1(1mg·kg)治疗 10 天。XMU-MP-1 治疗的小鼠比对照组小鼠具有更好的心脏收缩能力。XMU-MP-1 治疗的小鼠的心肌细胞横截面积和肥大标志物脑钠肽的表达减少。XMU-MP-1 治疗的 TAC 小鼠心脏功能改善,同时 TUNEL 阳性心肌细胞减少,纤维化程度降低,提示抑制心肌细胞凋亡和减少纤维化。
Hippo 通路抑制剂 XMU-MP-1 减少了培养的心肌细胞中的细胞肥大并提高了细胞存活率,并且在压力超负荷后体内保留了心脏功能。